Evolus reported Q2 2026 results on August 5, 2026, delivering revenue growth that beat guidance and marking the third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 financial outlook, signaling sustained momentum in Jeuveau adoption and market share gains.
For medspa owners, Evolus's profitability and guidance raise matter because a financially healthy competitor with cash flow can invest in rebate programs, direct sales to aesthetics practices, and brand-building—exactly what the material event filing suggests is underway. Evolus Rewards is now backed by a company with runway to sustain aggressive pricing.